A case-control study on the oxidative balance of 50% autologous serum eye drops by Gus, Patricia Ioschpe et al.
Research Article
A Case-Control Study on the Oxidative Balance of 50%
Autologous Serum Eye Drops
Patrícia Ioschpe Gus,1,2 Diane Marinho,3 Samira Zelanis,3
Adriane Belló-Klein,3 Claudete Locatelli,2 Felipe Nicola,3 Ana Laura Kunzler,3
Tania Regina Gatelli Fernandes,4 Cristina Campos Carraro,3 and Luciene Barbosa5
1Faculty of Medicine, Universidade Federal de Sa˜o Paulo, 04023-062 Sa˜o Paulo, SP, Brazil
2Hospital de Cl´ınicas de Porto Alegre, 90035-903 Porto Alegre, RS, Brazil
3Faculty of Medicine, Universidade Federal do Rio Grande do Sul, 90035-190 Porto Alegre, RS, Brazil
4Laboratory of Cardiovascular Physiology, Universidade Federal do Rio Grande do Sul, 90035-190 Porto Alegre, RS, Brazil
5Department of Ophthalmology, Universidade Federal de Sa˜o Paulo, 04023-062 Sa˜o Paulo, SP, Brazil
Correspondence should be addressed to Patr´ıcia Ioschpe Gus; patriciagus@me.com
Received 3 June 2016; Accepted 21 July 2016
Academic Editor: Alessandra Ricelli
Copyright © 2016 Patr´ıcia Ioschpe Gus et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Importance. Autologous serum (AS) eye drops are recommended for severe dry eye in patients with ocular surface disease. No
description of the antioxidant balance of AS eye drops has been reported in the literature. Objective.This study sought to evaluate
the total reactive antioxidant potential (TRAP) and concentration of reactive oxygen species (ROS) in samples of 50% AS eye
drops and their correlations with the demographic characteristics and lifestyle habits of patients with ocular surface disease and
healthy controls. Design. This was a case-control study with a 3-month follow-up period. Participants. 16 patients with severe dry
eye disease of different etiologies and 17 healthy controls matched by age, gender, and race were included. Results. TRAP and ROS
were detected at all evaluated times. There were no differences in the mean ROS (𝑝 = 0.429) or TRAP (𝑝 = 0.475) levels between
cases and controls. No statistically significant differences in the concentrations of ROS or TRAPs were found at 0, 15, or 30 days (𝑝
for ROS = 0.087 and 𝑝 for TRAP = 0.93). Neither the demographic characteristics nor the lifestyle habits were correlated with the
oxidative balance of the 50% AS eye drops. Conclusions and Relevance. Both fresh and frozen 50%AS eye drops present antioxidant
capacities and ROS in an apparently stable balance. Moreover, patients with ocular surface disease and normal controls produce
equivalent AS eye drops in terms of oxidative properties.
1. Introduction
Dry eye is a common disorder of the tear film that affects
millions of people over the age of 40 years worldwide, and
there is currently no cure for this disease [1]. Artificial
tears provide lubrication but lack the biologically active
components found in natural tears, which have a complex
composition that includes water, salts, hydrocarbons, pro-
teins, and lipids. Additionally, the frequent application of
artificial tear solutions containing chemical preservatives to
prevent contamination has been found to induce toxic and
allergic reactions, especially among those with sensitive eyes
[2, 3].
Eye drops that are produced by separating the liquid and
cellular components of a patient’s blood have been demon-
strated to possess many of the same biological nutrients that
are found in natural tears [1, 4–6]. Serum and tears show sim-
ilar constituent concentrations, with the exception of greater
amounts of vitamin A, lysozyme, transforming growth
factor-𝛽 (TGF-𝛽), and fibronectin and reduced amounts of
immunoglobulinA (IgA), epithelial growth factor (EGF), and
vitamin C in serum compared with tears [1, 2, 4]. The use
of autologous serum (AS) eye drops has been reported for
the treatment of severe dry eye and ocular surface disorders,
such as Sjo¨gren’s syndrome (SS), superior limbic kera-
toconjunctivitis, graft-versus-host disease, Stevens-Johnson
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syndrome, ocular cicatricial pemphigoid, recurrent corneal
erosions, neurotrophic keratopathy, Mooren’s ulcer, aniridic
keratopathy, and postkeratorefractive surgery. AS eye drops
are prepared as unpreserved diluted blood solutions [1, 7–9].
Due to its localization and function, the cornea is chroni-
cally exposed to ROS accumulation as well as to the oxida-
tive stress; however, normal corneas have well-developed
antioxidant defense systems which contain direct free radical
scavengers such as glutathione peroxidase, superoxide dis-
mutase, catalase, lactoferrin, and calcium [10–12]. In specific
conditions, the increased ROS production and accumula-
tion, the oxidative stress, and the prooxidant/antioxidant
imbalance lead to the corneal pathologies, including ocular
surface disease and dry eye syndrome [12–15]. Mitochondria-
induced oxidative damage is strongly related to lacrimal gland
inflammation and dysfunction, which was shown to result
in dry eye disease in a conditional transgenic mouse model
[16]. Increased oxidative stress in the conjunctivas of SS
patients also appears to play a role in the pathogenesis of dry
eye disease. Furthermore, the relationship between reactive
oxygen species (ROS) production and lipid peroxidation-
related membrane damage and inflammatory processes has
been observed in dry eye patients with SS [10]. According to
some studies, tobacco, UV radiation, photochemical stress,
ozone, smoke, and exhaust gases can cause dry eye due to
inflammation and ROS formation [17].
There is no information in the literature related to the
oxidative balance of AS eye drops. However, knowledge
regarding the antioxidant properties of AS eye drops might
aid the understanding of the mechanism of action of AS
eye drops in dry eye patients. This study measured the total
reactive antioxidant potential (TRAP) and the concentrations
of free radicals (ROS) in 50% AS eye drops and correlated
the results with the demographic characteristics and lifestyle
habits of patients with ocular surface disease and healthy
controls.
2. Patients and Methods
Sixteen patientswith ocular surface disease of different etiolo-
gies and 17 healthy controls matched for age and gender were
enrolled to obtain 50%AS eye drops that were produced with
their donated blood, which was acquired via venipuncture.
3mL samples were generated from the 30 vials of AS eye
drops that are typically produced monthly for each patient at
the Ophthalmology Service of Hospital de Cl´ınicas de Porto
Alegre (HCPA). Additional 3mL samples were produced
from blood donated by controls and used for biochemical
evaluation.
All patients and controls completed a questionnaire
regarding demographic characteristics (e.g., age and gender),
behavioral habits (smoking, alcohol, vegetables, fruit and
grain intakes, exercise, and synthetic vitamin use), andmedi-
cal diagnoses and signed an informed consent document that
was approved by the Ethical Committee of HCPA.
Preparation of the 50% AS Eye Drops. The AS eye drops
were prepared at the Molecular Analysis Unit of HCPA’s
Protein Research Center (UAMP) following the standards of
the InfectionCommission. Approximately 5mL of peripheral
venous blood was collected from the controls, and 150mL
was collected from the cases. The samples were centrifuged
at 2,500 rpm for 10 minutes at room temperature 1 hour after
venipuncture. The sera were removed from the tubes and
added to 0.5% unpreserved methylcellulose at 1 : 1 dilution
with laminar flow.
Biochemical Evaluation. Three Eppendorf vials containing
1.0mL 50% AS eye drops from each patient and control were
analyzed at the following 3 time points:
Time 0: fresh AS eye drops; the biochemical evalua-
tions were performed up to 48 hours after prepara-
tion.
Time 1: frozen AS eye drops, maintained at −20∘C for
15 days and then thawed for analysis.
Time 2: frozen AS eye drops, maintained at −20∘C for
30 days and then thawed for analysis.
The biochemical evaluations measured TRAP, which was
predominantly determined by glutathione and ascorbic acid,
and ROS, which were mainly composed of superoxide and
hydrogen peroxide. Details of the evaluations are provided
below.
TRAP represents the nonenzymatic antioxidant capacity
of the tissue as determined by measuring the intensity of
luminol (LH2) chemiluminescence induced by the addition
of 2,2󸀠-azobis(2-amidinopropane) (ABAP) at ambient tem-
perature. This method is based on the oxidative induction
time of lipid dispersion exposed to ABAP, which represents a
source of free radicals with a constant and known production
rate. For the basal chemiluminescence count, 4 𝜇L of 10mM
glycine buffer was added to the ABAP solution. Next, 10𝜇L
of 80mM Trolox glycine buffer (water soluble vitamin E,
which is the gold standard) or 10 𝜇L of tears (test sample)
was added to the ABAP buffer solution. In both solutions,
the chemiluminescence intensity due to LH2 is reduced as
antioxidants are consumed. The time required for the count
to return to the initial known value is proportional to the
antioxidant capacity, and these times for the Trolox (vitamin
E) and tear solutions were compared. This standard curve is
constructed with three crescent concentrations of Trolox (in
𝜇M). Antioxidant capacity of samples is calculated based on
the standard curve, one Trolox unit being correspondent to
1 𝜇M, and the results are expressed as 𝜇M. TRAP was mea-
sured in a beta counter (LKB Rack Beta Liquid Scintillation
Spectrometer 1215, LKB-Produkter AB, Bromma, Sweden).
ROS generation was measured based on the fluorescence
emission of dichlorofluorescein diacetate (DCF-DA) (Sigma-
Aldrich, SL, USA). DCF-DA permeates the cell membrane
and is rapidly oxidized by intracellular ROS to form the
compound 2,7-dichlorofluorescein (DCF), which is highly
fluorescent. The samples were excited at 488 nm, and the
emission at 525 nm was collected. The results are expressed
in nmol per mg of protein.
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Table 1: Questionnaire variables.
Demographic
characteristics, behavioral
habits, and medical
diagnoses
Number of
patients among
cases (𝑁 = 16)
Number of
patients among
controls (𝑁 = 17)
Mean age 43,6 43,4
Gender
Male 7 7
Female 9 10
Smoking 1 2
Alcohol intake 3 7
Fruit intake 15 15
Vegetables intake 10 15
Cereals intake 11 13
Vitamin supplementation 9 6
Physical exercises 7 13
Systemic disease
Arterial hypertension 6 3
Rheumatic disease 4 1
Diabetes mellitus 0 0
Other 0 4
3. Statistical Analysis
The descriptive data were collected, and the means were
compared using generalized linear models. Mann-Whitney
and Kruskal-Wallis tests were used for the nonparametric
analyses of independent samples.The number of samples was
calculated to provide a power of 95%.The data were analyzed
with IBM SPSS 22 statistical software.
4. Results
A total of 33 subjects were included (16 cases and 17 controls).
Forty-seven percent of the subjects were male. Question-
naire variables (Table 1) exhibited no relationships with the
independent variables tested (Table 2). The TRAP and ROS
concentrations were identified in all samples. There were no
differences in the mean concentrations of ROS (𝑝 = 0.429)
or TRAP (𝑝 = 0.475) between the cases and controls. There
were no differences in the TRAP or ROS concentrations in
the samples from each individual over time (𝑝 = 0.361).
Furthermore, when all of the 3 ROS and TRAP values from
the different time points were compared between groups, no
differences were found (𝑝 for ROS = 0.087 and 𝑝 for TRAP =
0.93; Table 3 and Figures 1 and 2).
5. Discussion
TheDefinition and Classification Subcommittee of the Inter-
national Dry Eye Work Shop [18] redefined dry eye as a
multifactorial disease of the tears and ocular surface which
results in symptoms of discomfort (including foreign body
sensations, dryness or irritation, burning, light sensitivity,
and redness), visual disturbances, and tear film instability
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Figure 1: ROS concentration over time: cases × controls.
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Figure 2: TRAP concentration over time: cases × controls.
with potential damage to the ocular surface. Dry eye is
accompanied by an increased osmolarity of the tear film
and inflammation of the ocular surface. Recent studies have
demonstrated that oxidative stress is involved in the patho-
genesis of dry eye disease, keratoconus, bullous keratopathy,
and Fuchs endothelial dystrophy [18–20]. In addition, higher
levels of ROS, lipid oxidative stress markers, and inflamma-
tory cells have been found in the conjunctiva and tear film
of SS patients [10]. However, few studies have comprehen-
sively investigated the relationship between hyperosmolarity
and oxidative damage on the human ocular surface or the
antioxidant properties of therapeutic preparations [21].
IoschpeGus et al. first reported the antioxidant properties
of the tears of healthy individuals, which were acquired
via lacrimal stimulation. The study by Ioschpe Gus et al.
employed the same technique of TRAP detection as the
present study [11]. Based on the results of both studies, 50%
SA eye drops seem to contain TRAP concentrations that are
approximately five to six times greater than TRAP in the
natural tears of young and healthy individuals. Ioschpe Gus
et al. did not measure ROS in tears.
The oxidative stress components and antioxidant prop-
erties seem to remain stable over time in both fresh and
thawed samples. This finding is interesting because patients
must use several vials of AS, as each vial is used for a
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Table 2: Correlation between ROS (day 0) and TRAP (day 0) percentiles distribution versus demographic characteristics and lifestyle habits.
Age Smoke Gender Alcohol Fruits Vegetables Cereals Vitamins Exercise Systemic diseases
TRAP
Day 0 𝑝 = 0.15 𝑝 = 0.38 𝑝 = 0.58 𝑝 = 0.31 𝑝 = 0.75 𝑝 = 0.27 𝑝 = 0.84 𝑝 = 0.45 𝑝 = 0.16 𝑝 = 0.77
ROS
Day 0 𝑝 = 0.98 𝑝 = 0.95 𝑝 = 0.55 𝑝 = 0.10 𝑝 = 0.16 𝑝 = 0.32 𝑝 = 0.96 𝑝 = 0.97 𝑝 = 0.84 𝑝 = 0.81
Table 3: ROS andTRAP’smeans pairwise comparison between days
0, 15, and 30.
ROS (pmol/mg) TRAP (𝜇M)
Day 0 versus day 15 11.88 versus 7.93(𝑝 = 0.815)
147.90 versus
135.44
(𝑝 = 0.47)
Day 0 versus day 30 11.88 versus 6.59(𝑝 = 0.497)
147.90 versus
132.26
(𝑝 = 0.777)
Day 15 versus day 30 7,93 versus 6.59(𝑝 = 0.194)
135.44 versus
132.26
(𝑝 = 1,000)
maximum of approximately 48 h, and some of the last vials
are thawed 30 days after preparation. Moreover, ROS stability
allows the authors to infer that there is no microorganisms’
contamination over time, since it would cause the rise of
ROS in samples [22]. The authors could not find comparable
studies about the concentration of ROS in tears.
Although many systemic diseases are oxidative stress-
related, and lifestyle might influence the oxidative balance
in general, no differences in the antioxidant properties of
the AS eye drops made from the cases and controls in the
present study were found. This finding is important because
it demonstrates that patients with ocular disease with and
without systemic pathologies might be capable of producing
high-quality AS eye drops in terms of their antioxidant
properties.
AS eye drops improve the quality of life of severe dry
eye patients, although reports of the correlation between
this improvement and clinical measurements are scarce in
the literature. The lack of an agreed on standard dilution
of serum for use in anterior segment applications has led
to concentrations from 20% to undiluted serum reported
in studies for dry eye disease or persistent epithelial defects
[5]. Based on data reported in different studies, 20% AS eye
drops are not associated with significant improvements in
aqueous tear production as measured with Schirmer’s test
or improvements in the condition of the ocular surface as
measured by fluorescein or Rose Bengal staining compared
with preservative-free artificial tears [1]. Regarding tear film
stability as measured by the tear breakup time (TBUT), only
Kojima et al. (2005) found a clinically meaningful difference
between 20% AS eye drops and artificial tears in participants
with SS and non-SS dry eye after two weeks of treatment [23].
Other studies using 50% AS eye drops show improvement in
Schirmer scores and effectiveness in treatment of persistent
corneal epithelial defects [24, 25]. Fifty percent AS dilution
with preservative-free methylcellulose 1 : 1 is routinely used
at HCPA because the authors believe it provides better
symptomatic relief. Moreover, the clinical evidence suggests
that 50%AS eye drops produce dry eye disease improvements
without the immune reaction that 100% AS eye drops might
produce [1].
This is the first paper to present data regarding the
oxidative balance of autologous serum eye drops and the
behavior of this balance over time. In particular, our results
demonstrated a difference between the antioxidant concen-
tration of 50% AS eye drops and natural tears compared to
the literature [11], which might explain the strong subjective
relief patients report following the use of the 50%AS prepara-
tion. The authors strongly recommend further investigations
comparing different concentrations of AS in terms of their
antioxidant potential and ROS levels and objective clinical
measurements in dry eye patients.
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